Join ALZpath at Clinical Trials on Alzheimer’s Disease (CTAD) Dec. 1-4 in San Diego
ALZpath Logo
Contact Us

Publications

Research Featuring the ALZpath pTau217 Antibody

Global studies confirm the ALZpath pTau217 antibody’s reliability and clinical utility in Alzheimer’s disease research and diagnosis.

Backed by over 100 peer-reviewed publications in just two years, the ALZpath pTau217 antibody has become integral in research detecting Alzheimer’s disease pathology. These studies collectively demonstrate ALZpath pTau217’s clinical utility, analytical robustness, and real-world applicability.

All Publications

Blood phosphorylated tau for the diagnosis of Alzheimer’s disease: a systematic review and meta-analysis

  • 2025
  • Authors: Therriault et al
View Publication

Integrating MRI Volume and Plasma p-Tau217 for Amyloid Risk Stratification in Early-Stage Alzheimer Disease

  • 2025
  • Authors: Yim et al
View Publication

Moderating effects of plasma glial fibrillary acidic protein along the Alzheimer’s disease continuum

  • 2025
  • Authors: Lee et al
View Publication

Real world diagnostic performance of plasma p-tau217 for early-onset Alzheimer’s disease in a cognitive disorders tertiary care setting

  • 2025
  • Authors: Chatterjee et al
View Publication

Plasma proteomic associations with Alzheimer’s disease endophenotypes

  • 2025
  • Authors: Afshar et al
View Publication

Diagnostic performance of Alzheimer’s disease blood and CSF biomarkers in a Brazilian cohort with low educational attainment

  • 2025
  • Authors: Borelli et al
View Publication

Preclinical dementia rating scores are associated with plasma phosphorylated tau‐217

  • 2025
  • Authors: Huang et al
View Publication

Neuropathologic correlates of distinct plasma biomarker profiles in community-living older adults

  • 2025
  • Authors: Yu et al
View Publication

Prognostic Value of A/T/N Biomarkers Comparing Plasma and Imaging Modalities in Alzheimer Disease

  • 2025
  • Authors: Yim et al
View Publication

Plasma and neurostructural biomarkers in the clinical-biological characterization of early stages of the Alzheimer’s disease continuum: findings from the Compostela Aging Study

  • 2025
  • Authors: Zurron et al
View Publication

Lifestyle, genetic risk, plasma pTau217, and incident cognitive impairment in WRAP

  • 2025
  • Authors: Studer et al
View Publication

Cognitive impairment and p-tau217 are high in a vascular patient cohort

  • 2025
  • Authors: French et al
View Publication

Mapping Alzheimer’s disease pathology using free water through integrated analysis of plasma biomarkers, microstructural DTI metrics, and macrostructural MRI measures

  • 2025
  • Authors: Kim et al
View Publication

Optimizing timing and cost-effective use of plasma biomarkers in Alzheimer’s disease

  • 2025
  • Authors: Chang et al
View Publication

The Relationship of Alzheimer’s Disease and Related Dementias Blood‐Based Biomarkers and Informant‐Reported Neuropsychiatric Symptoms Differs by Informant Type in Older Adults Without Dementia

  • 2025
  • Authors: Bacci et al
View Publication

The plasma p-tau217/BD-tau ratio improves biomarker short-termvariability in memory clinic patients

  • 2025
  • Authors: Clemmensen et al
View Publication

Profiling Plasma Biomarkers, Particularly pTau217 and pTau217/Aβ42, and Their Relation to Cognition in Memory Clinic Patients

  • 2025
  • Authors: Bucci et al
View Publication

Sex and ethnicity in early‐onset Alzheimer’s disease biomarkers and global function

  • 2025
  • Authors: Asken et al
View Publication

Plasma phosphorylated tau 217 and amyloid‑β 42/40 for amyloid risk in subgroups

  • 2025
  • Authors: Kang et al
View Publication

Potential utility of plasma pTau217 for assessing amyloid and tau biomarker profiles

  • 2025
  • Authors: Shin et al
View Publication

Comprehensive Evaluation of plasma tau biomarkers for detecting and monitoring alzheimer’s disease in a multi-center and multi-ethnic aging population

  • 2025
  • Authors: Lan et al
View Publication

Pregnancy hypertension is associated with higher p-tau217 in healthy midlife women

  • 2025
  • Authors: Yong et al
View Publication

Plasma biomarkers identify brain ATN abnormalities in a dementia-free population-based cohort

  • 2025
  • Authors: Dresse et al
View Publication

Pittsburgh plasma p-tau217: Classification accuracies for autosomal dominant and sporadic Alzheimer’s disease in the community

  • 2025
  • Authors: Sehrawat et al
View Publication

Impact of racialization on neuroimaging and plasma biomarkers of Alzheimer’s disease

  • 2025
  • Authors: Gogola et al
View Publication
Load More